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Abstract
The n−3 fatty acids are not produced by mammals, although they are essential for hormone synthesis and maintenance of cell
membrane structure and integrity. They have recently been shown to inhibit inflammatory reactions and also emerged as potential
treatment options for inflammatory diseases, such as rheumatoid arthritis, asthma and inflammatory bowel diseases. Dendritic cells
(DC) play a central role in the regulation of both innate and adaptive immunity and upon inflammatory signals they produce various
soluble factors among them cytokines and chemokines that act as inflammatory or regulatory mediators. In this study we monitored
the effects of α-linoleic acid, eicosapentaenoic acid and docosahexaenoic acid solubilized in a dimethyl sulfoxide (DMSO)/ethanol
1:1 mixture or as complexed by randomly methylated α-cyclodextrin (RAMEA) on the inflammatory response of human monocyte-
derived dendritic cells (moDC). The use of RAMEA for enhancing aqueous solubility of n−3 fatty acids has the unambiguous
advantage over applying RAMEB (the β-cyclodextrin analog), since there is no interaction with cell membrane cholesterol. In vitro
differentiated moDC were left untreated or were stimulated by bacterial lipopolysaccharide and polyinosinic:polycytidylic acid,
mimicking bacterial and viral infections, respectively. The response of unstimulated and activated moDC to n−3 fatty acid treat-
ment was tested by measuring the cell surface expression of CD1a used as a phenotypic and CD83 as an activation marker of
inflammatory moDC differentiation and activation by using flow cytometry. Monocyte-derived DC activation was also monitored
by the secretion level of the pro- and anti-inflammatory cytokines IL-1β, TNF-α, IL-6, IL-10 and IL-12, respectively. We found that
RAMEA-complexed n−3 fatty acids reduced the expression of CD1a protein in both LPS and Poly(I:C) stimulated moDC signifi-
cantly, but most efficiently by eicosapentaenic acid, while no significant change in the expression of CD83 protein was observed.
The production of IL-6 by LPS-activated moDC was also reduced significantly when eicosapentaenic acid was added as a RAMEA
complex as compared to its DMSO-solubilized form or to the other two n−3 fatty acids either complexed or not. Based on these
results n−3 fatty acids solubilized by RAMEA provide with a new tool for optimizing the anti-inflammatory effects of n−3 fatty
acids exerted on human moDC and mediated through the GP120 receptor without interfering with the cell membrane structure.
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Introduction
The n−3 polyunsaturated fatty acids (omega-3 or n−3 PUFAs)
contain multiple isolated carbon–carbon double bonds starting
at the third carbon atom counting from the end of the molecule.
The three main representatives involve α-linoleic acid (ALA,
C18:3), eicosapentaenoic acid (EPA, C20:5) and docosa-
hexaenoic acid (DHA, C22:6), which can be found in plants
(flaxseed, walnut) and fish oil, respectively. ALA and linoleic
acid (LA, C18:3 n−6 having the first double bond at the 6th
carbon atom from the chain end, therefore classified as n−6
PUFA) are essential fatty acids, because they cannot be synthe-
sized by the human body. ALA can be converted to EPA and
DHA [1], while LA is converted to arachidonic acid (AA,
C20:4 n−6), the precursor of prostaglandins and related com-
pounds playing crucial roles in inducing inflammatory reac-
tions. EPA is the precursor of prostanoids with less inflamma-
tory potential. DHA is a component of the phospholipid
membranes found everywhere in the body [2]. Changes in the
balance of n−3 and n−6 PUFAs in the diet upon low intake of
n−3 PUFAs have been linked to several inflammation-related
chronic diseases and certain mental illnesses [3].
Greenland Inuits with traditionally high seafood intake
containing large quantities of n−3 PUFAs were found to show
low morbidity rate from coronary heart disease [4]. Dietary
supplementation with n−3 PUFA significantly decreased the
risk of death after myocardial infarction [5]. Other studies also
showed that n−3 fatty acids can change beneficially the blood
lipid profile by decreasing the levels of triglyceride and very-
low-density lipoprotein (VLDL) without reducing the level of
low-density lipoprotein (LDL) [6]. Based on these data n−3
PUFAs have been considered as important contributors of the
prevention and/or modulation of various human diseases [7].
Intake of dietary fats may influence inflammation in the
gastrointestinal tract. In a long-term study conducted on
170 805 women a reduced risk of ulcerative colitis was
observed for the participants with high intake of n−3 PUFAs
[8]. The fatty acid composition of the diet, in particular, the
proportion of different types of PUFAs, has an influence on the
fatty acid composition of immune cells which is a chemical
trigger for immune response, such as inflammation [9]. Supple-
mentation of the diet of healthy human volunteers with n−3
PUFAs was unambiguously beneficial: the number of mono-
cytes and the concentration of proinflammatory cytokines were
reduced. Both animal experiments and clinical studies
confirmed that fish oil supplementation was helpful in rheuma-
toid arthritis, inflammatory bowel disease, and certain types of
asthma [5]. It was concluded that n−3 PUFAs in fish oil exhibit
anti-inflammatory and immunomodulatory effects.
Recent studies also showed that the treatment of humans with
ALA, EPA and/or DHA resulted in decreased expression of
pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α and
were able to modulate DC to a direction that resulted in reduced
cytotoxic T-cell responses and decreased level of inflammation.
Furthermore, the secretion of the T-cell polarizing cytokines
IL-10 and IL-12 was also modulated in a concentration-depen-
dent manner [10-14].
In these studies PUFAs were solubilized in organic solvents,
such as dimethyl sulfoxide (DMSO) with or without ethanol,
because they could not be dissolved in water owing to their long
alkyl chains. However, solubilization of PUFAs could also be
achieved by aqueous cyclodextrin (CD) solutions, which
allowed us to avoid organic solvents. CDs are cyclic oligo-
saccharides consisting of 6, 7 or 8 glucopyranose units (α-, β-
and γ-CDs, respectively). They form a hollow cylindrical struc-
ture with a rather hydrophobic inner cavity, which readily
adopts hydrophobic molecules forming inclusion complexes
[15]. One of the most important effects of complexation is the
enhanced solubility of poorly soluble compounds offering
numerous possibilities for application especially in the develop-
ment of improved pharmaceutical formulations [16]. The highly
soluble CD derivatives, especially the methylated ones possess
in most cases better solubilizing potential than their non-deriva-
tized variants [17]. The solubilizing efficiency depends on the
type, number and position of the substituents [18,19]. For
example, water soluble palmitic acid and myristic acid
complexed by RAMEB could be used for cultivation of other-
wise non-cultivable leprosy-derived psychrophilic mycobac-
teria [20].
The methylated β-CDs are used as cholesterol depleting agents
to disrupt caveolae and lipid rafts in the cell membrane as well
as for replenishment of cholesterol in the form of water-soluble
cholesterol/methyl β-CD complex to clarify the role of lipid
rafts in various cellular processes [21,22]. For instance, DHA
exerted anti-inflammatory effects via inhibition of the expres-
sion of cytokine-induced adhesion molecules in primary human
retinal vascular endothelial (hRVE) cells, the target tissue
affected by diabetic retinopathy [23]. To study whether the lipid
rafts were involved in the mechanism of action, methylated
β-CD was used for both the removal and the replenishment of
cholesterol from cells treated by DHA. The methylated β-CD
removes not only cholesterol but also some phospholipids from
the membrane thus inhibiting the efflux function of P-glycopro-
tein [24,25], and at higher concentrations induces apoptosis in
the rat alveolar cell line NR8383, in human alveolar basal
epithelial lung A549 adenocarcinoma cells and in the T-cell
Beilstein J. Org. Chem. 2014, 10, 3152–3160.
3154
leukemia cell Jurkat, respectively [26]. On the contrary, the
methylated α-CD derivatives showed no interaction with
membrane cholesterol and did not cause apoptosis in these cells
[24].
The effect of methylated β-CD was also studied in immune cells
and revealed the influence of cholesterol-content on the modu-
lation of the T cell membrane, and also on the function of Jurkat
cells as reviewed by Fülöp et al. [27]. Modulation of the choles-
terol content in the cellular membrane with methylated β-CD
seems to be an effective immunomodulatory intervention
against immunosenescence with aging [28]. In other studies
methylated β-CD used at high concentrations was found to
inhibit the activation of lymphocytes while at low concentra-
tion (3–4 mM) it accelerated the proliferation of human periph-
eral blood mononuclear cells [29]. All these effects of methyl-
ated β-CD are based on the interaction with cholesterol.
The chemical structure of RAMEA is shown in Figure 1. The
chemical structure of the n−3 PUFAs used for moDC treat-
ments are shown in Figure 2.
Figure 1: Structure of RAMEA.
The selection of human dendritic cells (DC) for monitoring the
effects of n−3 PUFAs was based on our previous results demon-
strating that the development of human monocyte-derived DC
(moDC) is highly sensitive to environmental cues among them
the level and composition of lipids and fatty acids [30]. These
studies also revealed the phenotypic and functional hetero-
geneity of these cells depending on the actual tissue microenvi-
ronment that is able to drive monocyte differentiation either to
inflammatory or to tolerogenic directions [31]. In the past
decade it was also discovered that phylogenetically ancient
Toll-like receptors (TLR) play essential roles in the recognition
of conserved molecular patterns, which are able to alarm the
innate immune system for fighting against invading pathogens
Figure 2: Structures of ALA, EPA and DHA.
and/or endogenous toxic or dangerous self molecules [32]. The
capability of moDC with high phagocytic activity and the
potential to translate the collected molecular information to
other cell types lead to the notion that different subtypes and
subsets of DC are central regulators of both innate and adaptive
immunity and thus they can also be harnessed for vaccine
development [33] and also for immunotherapeutic interven-
tions [34]. By using high throughput approaches we also identi-
fied genes and signaling pathways [35], which govern diverse
DC-associated functional activities such as mechanisms regu-
lating antiviral immunity differently by the CD1a positive and
CD1a negative moDC subsets [36]. Our recent studies focus to
uncovering collaborative and/or opposing activities of TLR to
gain insight to the inflammatory and regulatory networks
governing moDC functions in the presence of various exoge-
nous and/or endogenous signals [37]. In this context we identi-
fied distinct roles of human moDC types and subsets in
supporting antiviral immunity [38,39], histamine-mediated
modulation of moDC activities [40] and identified constraints of
moDC functions under inflammatory conditions [41].
In the present study we aim to compare the effects of n−3
PUFAs on the phenotypic characteristics and the functional
activities of human moDC activated by different inflammatory
stimuli on day 5 of the moDC differentiation process. To
compare the effects of ALA, EPA and DHA on moDC activi-
ties the cells were stimulated by bacterial lipopolysaccharide
(LPS), the specific ligand of Toll-like receptor 4 (TLR4) and by
synthetic polyinosinic:polycytidylic acid (Poly(I:C)) recog-
nized by Toll-like receptor 3 (TLR3) specific for double
stranded RNA (dsRNA). To avoid the interaction with choles-
terol in the DC membrane in our in vitro experiments we used a
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non-cholesterol interacting CD, i.e., randomly methylated α-CD
(RAMEA) for solubilization of n−3 PUFAs.
Results and Discussion
Solubilization of n−3 PUFAs
Cyclodextrins (CDs) are efficient solubilizers of lipids [42]. The
water-insoluble n−3 PUFAs were solubilized in aqueous solu-
tions of randomly methylated α- and β-CD (RAMEA and
RAMEB, respectively), but the similar γ-CD derivative,
RAMEG was ineffective to modulate the solubility (Figure 3),
while cholesterol could be dissolved by RAMEB only. Neither
RAMEA nor RAMEG could solubilize cholesterol to a measur-
able extent. The solubilizing effect of RAMEA in the case of
n−3 PUFAs seems to be high enough for using it as a solubi-
lizer without the risk of interaction with cholesterol-rich lipid
rafts in the cell membrane.
Figure 3: Solubility of n−3 PUFAs and cholesterol in water solutions of
20% randomly methylated α-, β- and γ-CDs (RAMEA, RAMEB and
RAMEG) compared to distilled water (control).
The complexation efficiency [43] calculated from the solubility
data characterize the affinity of the various methylated CDs
toward the lipids studied (Table 1). The complex association
constants were not calculated because the intrinsic solubility in
water is so low that it cannot be determined with a precision
sufficient for the calculations.
Table 1: Complexation efficiency for fatty acid and cholesterol with
randomly methylated CDs.
ALA EPA DHA Cholesterol
RAMEA 0.25 0.21 0.10 <0.001
RAMEB 0.43 0.41 0.35 0.08
RAMEG 0.012 0.012 <0.001 <0.001
The higher complexation efficiency corresponds to a higher
affinity for complexation which is manifested in a higher solu-
bilizing effect. Based on these results the inclusion complexes
with 1–3% PUFA content were prepared by applying RAMEA.
These complexes could readily be dissolved in water, and their
aqueous solutions were used for all experiments performed with
moDC.
Effects of RAMEA-solubilized PUFAs on the
expression of moDC cell surface proteins
Our previous results revealed that the expression of CD1a in
moDC is controlled by the nuclear hormone receptor peroxy-
some proliferator activated receptor gamma (PPARγ) and its
agonistic ligands are generated from poly-unsaturated fatty
acids derived from modified LDL or acquired from exogenous
sources assisted by ApoE [30]. We also found that the actual
lipid and lipoprotein environment of the cell can result in the
differentiation of two DC subsets identified by the expression
level of the CD1 membrane protein referred to as CD1a+ and
CD1a− cells [31]. The continuous survey of the intracellular
compartments of DCs is an important step in handling both
protein and lipid antigens. However, it occurs differently for
protein and glycolipid antigens as they use distinct intracellular
transporter pathways. Furthermore, in contrast to other CD1
proteins, CD1a has an exceptionally short cytoplasmic tale,
which is not associated with any adaptor molecule. Conse-
quently, CD1a can reach the cell surface directly from the
cytosol and also can acquire polar lipids from exogenous
sources [44].
Considering that the most important biological function of the
CD1a protein is the recognition, binding and presentation of
glycolipids for innate immune cells [32], we hypothesized that
upon interaction of lipids and fatty acids with various lipid
binding receptors may also have the potential to influence the
functional properties of moDC followed by internalization.
In our previous results CD1a+ moDC has been identified as an
inflammatory cell type that is able to provoke inflammation,
while its CD1a− counterpart is characterized by the production
of the anti-inflammatory cytokine IL-10 [33]. Based on these
regulatory circuits the expression of CD1a emerged as a
biomarker depending on the lipid and lipoprotein content of the
environment.
We designed experiments where in vitro differentiated moDC
were stimulated with LPS or Poly(I:C) mimicking bacterial and
viral infections, respectively or were left untreated and the
response of unstimulated and activated moDC was monitored
by measuring the expression levels of CD1a and the DC acti-
vation marker CD83 by flow cytometry. CD83 was selected for
monitoring DC activation based on its glycoprotein nature and
the potential to act as both an activation and supression marker
of DC depending on its monomeric or dimeric forms [45].
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Figure 4: The effect of n−3 PUFAs on the expression of CD1a cell surface protein in resting (red), LPS-activated (yellow) and Poly(I:C)-activated
(white) moDC (N = 6) (*p < 0.05 compared to the control).
Figure 5: Effect of n−3 PUFAs on the expression of the CD83 activation marker in resting (red), LPS-activated (yellow) and Poly(I:C)-activated (white)
moDC (N = 6) (*p < 0.05 compared to the control).
These functional attributes of CD83 offered us a potential tool
for dissecting the protein and lectin mediated functions of
CD83. However, our results demonstrated that PUFAs had no
effect on the expression of CD83.
Changes in moDC phenotype related to cell activation was
monitored and the secretion of pro- and anti-inflammatory
cytokines that involved IL-1β, TNF-α, IL-6 and the T-cell
polarizing cytokines IL-10 and IL-12, respectively was tested.
The effects of the two solubilization methods (organic solvent
and aqueous RAMEA solution) were also compared.
According to the results shown in Figure 4 the ratio of resting
CD1a+ cells did not change and remained in the range of
18–25% in the six individual donors tested, which could be
further decreased by treatment with n−3 PUFAs independently
on the mode of activation. Comparing the three n−3 PUFAs
dissolved in DMSO/ethanol, DHA turned out to be more effi-
cient in decreasing the proportion of inflammatory CD1a+ cells,
than ALA or EPA. The solubilization method did not influence
the effects of ALA and DHA, while the RAMEA-complexed
EPA further reduced the expression of CD1a protein on the
surface of moDC. The most efficient anti-inflammatory effect
on the ratio of the CD1a+ DC subset was detected by the EPA/
RAMEA complex. These results indicate that CD1a, acting as a
lipid/glycolipid receptor on the cell surface may also be
involved in the down modulation of CD1a expression by ALA,
EPA and DHA. One possible mechanism of this effect could be
the interference of n−3 PUFA with trafficking of CD1a proteins
to the cell surface.
Activation of DC with both LPS and Poly(I:C), being the
specific ligands of TLR4 and TLR3 receptors, respectively
resulted in enhanced expression of the CD83 cell surface
protein showing successful moDC activation (Figure 5).
However, the treatment of DC with n−3 PUFAs had no signifi-
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Figure 6: Effect of n−3 PUFAs on the expression of the pro-inflammatory cytokine IL-6 in moDC activated by LPS (A) or by Poly(I:C) (B) (N = 6)
(*p < 0.05 compared to the control).
cant impact on CD83 expression independent on the solubi-
lizing method used. This result suggested that CD83 is not the
direct target of the PUFA-mediated down modulatory effect.
Earlier studies have shown that the anti-inflammatory effect of
n−3 PUFAs is associated with the reduced production of pro-
inflammatory cytokines both in mouse and human DCs [10-14].
In our experimental system the secretion of interleukin-1β (IL-
1β), and tumor necrosis factor-α (TNF-α) was not influenced by
the treatment of n−3 PUFAs even though the secretion of both
cytokines could be enhanced markedly by both activators, i.e.,
LPS and Poly(I:C). In contrast, the level of IL-6 secreted by
activated moDC was much higher than that of the non-acti-
vated cells, which hardly produced any IL-6. Activation of
moDC by Poly(I:C) resulted in 1–2 orders of magnitude lower
levels of IL-6 production than cells activated by LPS (Figure 6).
The treatment with n−3 PUFAs did not cause significant
changes in this pattern, except EPA complexed with RAMEA,
which caused significant reduction in the level of Poly(I:C)-
induced IL-6 secretion.
Modulating the secretion of T-lymphocytes
polarizing cytokines by n−3 PUFAs
The T-lymphocyte polarizing cytokines IL-12 and IL-10,
produced by activated moDCs play a crucial role in the polariz-
ation of naïve CD4+ T-lymphocytes toward inflammatory or
tolerogenic directions. Previous studies demonstrated that n−3
PUFAs have the potential to decrease the production of both
cytokines [11,12]. To assess the effects of n−3 PUFAs on the
expression of IL-10 and IL-12 cytokines we measured the
expression levels of moDC-derived IL-10 and IL-12 by ELISA.
However, the treatment of PUFAs in our hands did not cause
such a decrease in cytokine secretion, although the secretion of
both cytokines was increased upon activation by LPS or
Poly(I:C), and no difference between the cells treated with any
of the 3 fatty acids could be detected (data not shown).
Similar results were obtained when moDC-induced T-cell
polarization was studied by the ELISPOT assay monitored by
the response of moDC-induced autologous T-lymphocytes
measured by IFNγ and IL-17 cytokine secretion. Interestingly,
we observed that the number of IL-17-producing T-cells
induced by Poly(I:C)-stimulated moDC gave rise to even lower
number of IL-17 producing cells than produced by non-acti-
vated or LPS-activated moDC suggesting that the down modu-
lation of moDC stimulation by n−3 PUFAs could be translated
to T-lymphocytes as an inhibitory/tolerogenic signal. Based on
these results we suggest that n−3 PUFAs act at the level of
innate immunity via down modulating selected functional activ-
ities of inflammatory moDCs, which also have the capability to
modify effector T-lymphocyte responses.
Effects of n−3 PUFAs on the expression of
the GPR120 receptor
G-protein-coupled receptor-120 is a membrane bound receptor
with 7 trans-membrane domains, which bind specifically to
long chain fatty acids. The ligands of GPR120 involve multi-
unsaturated long-chain fatty acids present in the outer
membrane of adipocytes, monocytes and dendritic cells. In
contrast to small chain fatty acids they play a role in the regula-
tion of body weight and glucose homeostasis, and when acti-
vated by omega-3 fatty acids, they support anti-inflammatory
effects by inhibiting inflammatory cytokine secretion via
signaling through the GPR120 receptor This occurs with the
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Figure 7: The effect of n−3 PUFAs on the expression of GPR120 receptor in resting (red), LPS-activated (yellow) and Poly(I:C)-activated (white)
moDC (N = 6) (*p < 0.05 compared to the control).
assistance of the adapter protein β-arrestin-2 that directly asso-
ciates with GPR120 [46].
To study the role of the GPR120 receptor in the regulation of
pro-inflammatory cytokine production we tested the
immunomodulatory effects on DCs by monitoring its expres-
sion levels in resting cells as compared to cells activated by
LPS or Poly(I:C). Our results showed that LPS-induced inflam-
mation caused decreased GPR120 expression and the treatment
with n−3 PUFAs further reduced the expression of this receptor
indicating consumption of the receptor induced preferentially
by DHA (Figure 7). Most importantly, the RAMEA-solubilized
EPA was also efficient to mediate this modulatory effect, while
Pol(I:C) exerted an adverse effect and resulted in slightly
elevated GPR120 expression indicating the involvement of
different regulatory pathway in LPS- and Poly(I:C)-induced
moDC modulation.
Conclusion
The n−3 PUFAs can be solubilized by aqueous RAMEA solu-
tions similarly to RAMEB without the risk of cholesterol
removal from the cell membrane. This solubilization method
avoids the use of organic solvents, which may be toxic for
differentiating and functional cells. The response of moDCs to
PUFA treatments induced by inflammatory stimuli and mimic-
king bacterial and viral infections demonstrated that the pheno-
type of activated moDCs could be modified and the secretion of
pro-inflammatory cytokines could be decreased as a result of
PUFA treatment. The anti-inflammatory effect of the n−3
PUFAs was also demonstrated by the decreased expression of
CD1a membrane protein in the cell surface, the decreased secre-
tion of the pro-inflammatory cytokine IL-6 and the PUFA-
mediated modulation of GPR120 receptor expression depen-
dent on the mode of moDC activation. The treatment of moDCs
with n−3 PUFAs showed no significant changes in the expres-
sion of the CD83 activation marker, in the secretion of IL-1β
and TNF-α cytokine secretion, and in the production of moDC-
mediated IFNγ and IL-17 cytokine production involved in
T-lymphocyte proliferation and activation. These results alto-
gether indicate the delicate regulation of PUFA-induced effects
on DC functional activities ultimately leading to a balancing
effect of inflammatory processes.
Comparison of the three fatty acids studied showed that they
could cause similar changes in most functions tested. Compari-
son of the two solubilizing methods (organic solvent and
aqueous cyclodextrin solution) revealed that RAMEA-solubi-
lized EPA was more effective in reducing the expression of
CD1a, the secretion of IL-6 and the down regulation of GPR120
receptor expression than EPA dissolved in DMSO/ethanol.
Based on these results n−3 PUFAs solubilized by RAMEA
provide with a new tool for optimizing the anti-inflammatory
effects exerted on human moDC and mediated via the GPR120
receptor without interfering with the cell membrane structure.
Experimental
Fatty acids, cyclodextrins
The fatty acids were purchased from Sigma-Aldrich. The
randomly methylated β-cyclodextrin (RAMEB, the number of
methyl groups/CD (DS) is 12) is the product of Wacker
Chemie, Munich, Germany, while the α- and γ-CD analogues
with DS 8.7 and 12.6 were produced by CycloLab, Hungary.
Solubility measurement
The solubility of fatty acids in CD solutions was determined by
adding PUFAs to the aqueous solutions at 20% RAMEA,
RAMEB or RAMEG, respectively, stirring for 24 h at rt and
then analyzed the filtered saturated solutions by HPLC using
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Hypersil ODS column (4 × 125 mm, particle size 5 μm) with
guard column, mobile phase: acetonitrile/water 75:25 with
0.15% concentrated phosphoric acid, 2.0 mL/min flow rate, at
40 °C and UV detection at 210 nm.
The PUFA/RAMEA complexes were prepared by lyophiliza-
tion of the filtered, saturated solutions. The fatty acid content of
the lyophilized complexes was 2.3%, 3.1% and 1.4% for ALA,
EPA and DHA complexes, respectively.
Isolation of primary human monocytes and differen-
tiation of monocyte-derived dendritic cells
Peripheral blood mononuclear cells (PBMC) were separated
from buffy coats by Ficoll gradient centrifugation (Amersham
Biosciences, Uppsala, Sweden). Monocytes were isolated by
positive selection using magnetic cell separation with anti-
CD14-conjugated microbeads (Miltenyi Biotech, Bergisch
Gladbach, Germany). The proportion of CD14+ cells was deter-
mined by flow cytometry and was found to be 96–99% depen-
dent on the blood donor. The purified cells were cultured at a
density of 106 cells/mL in serum free AIMV medium supple-
mented with 80 ng/mL granulocyte-macrophage colony stimu-
lating factor (GM-CSF) purchased from Gentaur and 50 ng/mL
IL-4 from Peprotech.
PUFA treatment of moDC
On day 0 and day 2 of the in vitro moDC differentiation process
the cultures were supplemented with GM-CSF and IL-4 and
were treated with 20 µM/mL n−3 PUFAs. On day 5 the fully
differentiated cells were activated by 500 ng/mL bacterial
lipopolysaccharide (LPS) (Sigma Aldrich) or by 500 ng/mL
Poly(I:C) (InvivoGen, San Diego, CA, USA) or were left
untreated. The negative controls were treated by DMSO or by
20 µM/mL RAMEA. The positive controls were stimulated by
LPS or Poly(I:C) in the absence of PUFAs.
Cytokine measurements
Supernatants of the activated moDC were collected on day 6 of
the differentiation process and the concentration of secreted
cytokines was determined by cytokine-specific OptEIA Set®.
Determination of cytokine levels was performed with StepOne-
Plus equipment (AB-Applied Biosystems) and was evaluated
with the help of the StepOne Software v2.1 and Excel.
Flow cytometry
Phenotyping of moDC was performed by flow cytometry using
anti-CD83-PE and anti-CD1a-FITC specific antibodes from
BioLegend at the protein level (San Diego, CA, USA). Fluores-
cence intensities were measured with FACSCalibur (BD
Biosciences). Data analysis was performed with the FlowJo
software (Tree Star, Ashland, OR, USA).
Determination of GPR120 expression levels
GPR120 expression levels were measured by real-time quanti-
tative PCR (Q-PCR). Total RNA was extracted using TRI
Reagent (Molecular Research Center, Inc., Cincinnati, OH,
USA) and was reverse-transcribed using the High Capacity
cDNA RT Kit of Applied Biosystems (Carlsbad CA). The
GPR120 gene expression assays were purchased from Applied
Biosystems. Results were normalized to the housekeeping gene
cyclophilin (Integrated DNA Technologies, Coralville, IA,
USA). Q-PCR was performed using the ABI StepOne Real
Time PCR System (Applied Biosystems) and cycle threshold
values were determined by using the StepOne v2.1 Software
(Applied Biosystems).
Statistical analysis
The results of flow cytometry, Q-PCR and ELISA studies were
analyzed by one-way ANOVA with Bonferroni post-hoc test
using the GraphPad Prism v.6 software (GraphPad Software
Inc., La Jolla, CA, USA). Differences were considered to be
statistically significant at p < 0.05.
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